

## Suven Life Sciences Achieves 25% Enrollment Milestone in Two Months for Ropanicant Phase-2b Clinical Trial in Patients with Major Depressive Disorder (MDD)

*The company continues to make significant progress in advancing clinical development of Ropanicant with anticipated last patient in (LPI) by March 2026*

**Hyderabad, India** (17-Sept-2025)- Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, today announced that its Phase-2b clinical study evaluating Ropanicant, a nicotinic  $\alpha 4\beta 2$  receptor antagonist for the treatment of Major Depressive Disorder (MDD), has successfully reached 25% of its enrollment goal within two months. The study being conducted exclusively in USA.

### Key Highlights of the Ropanicant Phase-2b Study:

- **Study Design:** The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA for a treatment duration of six weeks. The study will evaluate the efficacy and safety of Ropanicant in patients with MDD, compared to placebo, in improving symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). For more information about the Phase-2b study visit [ClinicalTrials.gov](https://ClinicalTrials.gov/Identifier/NCT06836063). Identifier NCT06836063.
- **Enrollment Progress:** Within two months of initiation, 25% of the targeted patient enrollment has been achieved. This rapid enrollment is indicative of the high level of interest among both clinical trial sites and patients.
- **Safety and Tolerability:** Safety data from the study are being monitored continuously, with no significant concerns raised to date.

Suven anticipates the last patient in (LPI) by March 2026. Topline data readout is expected by July 2026.

*“The strong pace of early enrollment represents a key milestone for Suven Life Sciences, the high level of interest in Ropanicant as a potential treatment for MDD, the unmet need in this disease and the operational strength of our clinical development team”* said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

*“We are encouraged by the current momentum and are focused on sustaining this progress with scientific rigor. We strongly believe Ropanicant with new mechanism of action, would offer a meaningful therapeutic option in the MDD landscape. We remain committed to advancing the program rapidly and look forward to sharing key clinical data in mid-2026”* said Dr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)

**About Ropanicant (SUVN-911):** Ropanicant is a novel, selective  $\alpha 4\beta 2$  receptor antagonist in development for MDD. It has shown strong efficacy in animal models of depression and may address key limitations of current treatments, including rapid onset of action, reduced sexual dysfunction, and enhanced cognitive function. Non-clinical safety has been established through extensive pharmacology and toxicity studies (up to 9 months). In Phase 1 trials, Ropanicant was safe and well tolerated at the highest doses, with no significant effects from food or age. The Phase-2a trial demonstrated a favorable safety profile and significant improvements in depressive symptoms, as measured by the MADRS score. Suven fully owns Ropanicant's intellectual property rights.

**About Suven Life Sciences:** Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

**Risk Statement:** *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad - 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)